FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
The FDA has accepted the Biologics License Application (BLA) for IMMGOLIS, a formulation of GOLIMUMAB-SLDI.
Therapeutic Area
Therapeutic area intelligence for TNF Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.